Insider · CIK 0001985547
Songjiang Ma
presidentofficerdirector
Files at GYRE (GYRE THERAPEUTICS, INC.). First filing Dec 19, 2024, latest May 29, 2025.
In brief
Songjiang Ma files SEC Form 4 as president and director at GYRE (GYRE THERAPEUTICS, INC.). Since Dec 19, 2024, Songjiang Ma has reported 0 open-market buys worth $0 and 38 open-market sells worth $1.5M, the latest filed on May 29, 2025.
A track record needs three past buys with six months of prices behind them; Songjiang Ma has 0, so none is measured yet.
The newest scored trade: sold $26k of GYRE on May 27, 2025, filed May 29, 2025, scored 5 (weak), under a 10b5-1 plan.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 38
$0 bought, $1.5M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GYRE: GYRE THERAPEUTICS, INC.
GYREOct 12, 2026 · close 6.87
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 5Weak | GYRE THERAPEUTICS, INC. | $26k 2,558 shares | -0% | +59% from low-39% from high | |
| 0Weak | GYRE THERAPEUTICS, INC. | $24k 2,182 shares | -0% | +75% from low-33% from high | |
| 6Weak | GYRE THERAPEUTICS, INC. | $44k 4,000 shares | -0% | +78% from low-32% from high | |
| 6Weak | GYRE THERAPEUTICS, INC. | $45k 4,000 shares | -0% | +77% from low-32% from high | |
| 0Weak | GYRE THERAPEUTICS, INC. | $22k 2,020 shares | -0% | +62% from low-38% from high | |
| 6Weak | GYRE THERAPEUTICS, INC. | $44k 4,000 shares | -0% | +69% from low-36% from high | |
| 0Weak | GYRE THERAPEUTICS, INC. | $1,740 174 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $40k 4,000 shares | -0% | - | |
| 5Weak | GYRE THERAPEUTICS, INC. | $27k 2,242 shares | -0% | - | |
| 7Weak | GYRE THERAPEUTICS, INC. | $48k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $46k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $41k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $44k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $44k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $45k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $46k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $45k 4,000 shares | -0% | - | |
| 7Weak | GYRE THERAPEUTICS, INC. | $49k 4,000 shares | -0% | - | |
| 7Weak | GYRE THERAPEUTICS, INC. | $49k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $46k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $45k 3,878 shares | -0% | - | |
| 7Weak | GYRE THERAPEUTICS, INC. | $50k 4,000 shares | -0% | - | |
| 7Weak | GYRE THERAPEUTICS, INC. | $48k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $46k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $46k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $45k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $43k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $43k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $43k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $42k 4,000 shares | -0% | - | |
| 0Weak | GYRE THERAPEUTICS, INC. | $11k 1,113 shares | -0% | - | |
| 0Weak | GYRE THERAPEUTICS, INC. | $22k 2,216 shares | -0% | - | |
| 7Weak | GYRE THERAPEUTICS, INC. | $48k 4,000 shares | -0% | - | |
| 7Weak | GYRE THERAPEUTICS, INC. | $50k 4,000 shares | -0% | - | |
| 7Weak | GYRE THERAPEUTICS, INC. | $51k 4,000 shares | -0% | - | |
| 7Weak | GYRE THERAPEUTICS, INC. | $48k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $43k 4,000 shares | -0% | - | |
| 6Weak | GYRE THERAPEUTICS, INC. | $45k 4,000 shares | -0% | - |
Transactions
The newest 50 of 86 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 27, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.28 | $21k | 2,806,642 | May 29, 2025 |
| May 28, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -558 | $10.07 | $5,619 | 2,806,084 | May 29, 2025 |
| May 22, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.97 | $22k | 2,808,824 | May 27, 2025 |
| May 23, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -182 | $10.24 | $1,864 | 2,808,642 | May 27, 2025 |
| May 20, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.25 | $23k | 2,812,824 | May 22, 2025 |
| May 21, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.83 | $22k | 2,810,824 | May 22, 2025 |
| May 16, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.31 | $23k | 2,816,824 | May 20, 2025 |
| May 19, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.11 | $22k | 2,814,824 | May 20, 2025 |
| May 14, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -20 | $11.30 | $226 | 2,820,824 | May 16, 2025 |
| May 15, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.68 | $21k | 2,818,824 | May 16, 2025 |
| May 12, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.56 | $21k | 2,822,844 | May 14, 2025 |
| May 13, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.37 | $23k | 2,820,844 | May 14, 2025 |
| Mar 21, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -174 | $10.00 | $1,740 | 2,824,844 | Mar 25, 2025 |
| Mar 19, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.13 | $20k | 2,827,018 | Mar 21, 2025 |
| Mar 20, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.09 | $20k | 2,825,018 | Mar 21, 2025 |
| Mar 17, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $12.09 | $24k | 2,829,260 | Mar 19, 2025 |
| Mar 18, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -242 | $10.24 | $2,478 | 2,829,018 | Mar 19, 2025 |
| Mar 13, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.80 | $24k | 2,833,260 | Mar 17, 2025 |
| Mar 14, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $12.31 | $25k | 2,831,260 | Mar 17, 2025 |
| Mar 11, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.40 | $23k | 2,837,260 | Mar 13, 2025 |
| Mar 12, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.74 | $23k | 2,835,260 | Mar 13, 2025 |
| Mar 7, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -53 | $13.03 | $691 | 2,843,207 | Mar 11, 2025 |
| Mar 7, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -41 | $12.14 | $498 | 2,843,166 | Mar 11, 2025 |
| Mar 7, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -1,906 | $10.13 | $19k | 2,841,260 | Mar 11, 2025 |
| Mar 10, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.14 | $20k | 2,839,260 | Mar 11, 2025 |
| Mar 5, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.98 | $22k | 2,845,260 | Mar 7, 2025 |
| Mar 6, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.80 | $22k | 2,843,260 | Mar 7, 2025 |
| Mar 3, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.23 | $22k | 2,849,260 | Mar 5, 2025 |
| Mar 4, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $10.86 | $22k | 2,847,260 | Mar 5, 2025 |
| Feb 27, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.33 | $23k | 2,853,260 | Mar 3, 2025 |
| Feb 28, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.41 | $23k | 2,851,260 | Mar 3, 2025 |
| Feb 25, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.37 | $23k | 2,857,260 | Feb 27, 2025 |
| Feb 26, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.63 | $23k | 2,855,260 | Feb 27, 2025 |
| Feb 21, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -1,818 | $11.84 | $22k | 2,861,442 | Feb 25, 2025 |
| Feb 21, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -182 | $12.60 | $2,293 | 2,861,260 | Feb 25, 2025 |
| Feb 24, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -1,813 | $10.60 | $19k | 2,859,447 | Feb 25, 2025 |
| Feb 24, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -187 | $11.52 | $2,154 | 2,859,260 | Feb 25, 2025 |
| Feb 19, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $12.29 | $25k | 2,865,260 | Feb 21, 2025 |
| Feb 20, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $12.40 | $25k | 2,863,260 | Feb 21, 2025 |
| Feb 14, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.94 | $24k | 2,869,260 | Feb 19, 2025 |
| Feb 18, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $12.49 | $25k | 2,867,260 | Feb 19, 2025 |
| Feb 12, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.49 | $23k | 2,873,260 | Feb 14, 2025 |
| Feb 13, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.69 | $23k | 2,871,260 | Feb 14, 2025 |
| Feb 10, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.90 | $24k | 2,877,138 | Feb 12, 2025 |
| Feb 11, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -1,878 | $11.52 | $22k | 2,875,260 | Feb 12, 2025 |
| Feb 6, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $12.85 | $26k | 2,881,138 | Feb 11, 2025 |
| Feb 7, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $12.16 | $24k | 2,879,158 | Feb 11, 2025 |
| Feb 4, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,000 | $11.62 | $23k | 2,885,138 | Feb 6, 2025 |
| Feb 5, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -1,980 | $12.39 | $25k | 2,883,158 | Feb 6, 2025 |
| Feb 5, 2025 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -20 | $12.84 | $257 | 2,883,138 | Feb 6, 2025 |
50 of 86 rows shown.
Questions about Songjiang Ma
Answered from the filings on this page, as of the latest one.
Is Songjiang Ma buying or selling?
Not in the last 12 months. Songjiang Ma's latest open-market trade on SEC Form 4 was sold $26k of GYRE on May 27, 2025.
How did Songjiang Ma's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Songjiang Ma has 0.
Where does Songjiang Ma file Form 4?
Songjiang Ma has filed Form 4 at GYRE (GYRE THERAPEUTICS, INC.) as President. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.